España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Neurocrine Biosciences
NBIX
NASDAQ
Watchlist
Get Report
Perks
Buy
Compare Brokers
$138.23
0.74
0.54%
At Close: -
$138.23
0
0.00%
After Hours: 1:08 PM EDT
15 minutes delayed
Get Report
Watch
Neurocrine Biosciences (NBIX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Neurocrine Biosciences (NASDAQ:NBIX) Stock
Neurocrine Biosciences Stock (NASDAQ: NBIX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, July 01, 2024
Neurocrine Biosciences' Crinecerfont Receives...
Benzinga Newsdesk
Wednesday, June 12, 2024
Morgan Stanley Maintains Overweight on Neuroc...
Benzinga Newsdesk
Monday, June 03, 2024
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Neurocrine Biosciences Presented Data For Its...
Benzinga Newsdesk
Neurocrine Biosciences' Crinecerfont Shows Re...
Benzinga Newsdesk
Wednesday, May 29, 2024
Wedbush Reiterates Outperform on Neurocrine B...
Benzinga Newsdesk
Tuesday, May 28, 2024
Neurocrine Biosciences shares are trading low...
Benzinga Newsdesk
Neurocrine Biosciences Says Kevin Gorman Will...
Benzinga Newsdesk
Key Takeaways From Neurocrine Biosciences Analyst Ratings
Benzinga Insights
Neurocrine Biosciences To Present Data From N...
Benzinga Newsdesk
UBS Maintains Buy on Neurocrine Biosciences, ...
Benzinga Newsdesk
Tuesday, May 21, 2024
Neurocrine Biosciences Phase 3 KINECT-4 Post ...
Benzinga Newsdesk
Tuesday, May 14, 2024
Neurocrine Biosciences Presents Data At ECE 2...
Benzinga Newsdesk
Evercore ISI Group Initiates Coverage On Neur...
Benzinga Newsdesk
Thursday, May 09, 2024
Neurocrine Biosciences Presents CAHtalyst Adu...
Benzinga Newsdesk
Nxera Pharma's Partner Neurocrine Biosciences...
Benzinga Newsdesk
Wednesday, May 08, 2024
Neurocrine Biosciences To Begin Initiation Of...
Benzinga Newsdesk
Tuesday, May 07, 2024
Neurocrine Biosciences To Present Phase 3 Bas...
Benzinga Newsdesk
Friday, May 03, 2024
Citigroup Maintains Neutral on Neurocrine Bio...
Benzinga Newsdesk
Thursday, May 02, 2024
Canaccord Genuity Maintains Buy on Neurocrine...
Benzinga Newsdesk
Guggenheim Maintains Buy on Neurocrine Biosci...
Benzinga Newsdesk
Barclays Maintains Overweight on Neurocrine B...
Benzinga Newsdesk
BMO Capital Maintains Market Perform on Neuro...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on Neurocrin...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Neurocri...
Benzinga Newsdesk
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Wednesday, May 01, 2024
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Benzinga Insights
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Neurocrine Biosciences Reiterates FY24 INGREZ...
Benzinga Newsdesk
Neurocrine Biosciences Q1 Adj $1.20 Beats $1....
Benzinga Newsdesk
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Tuesday, April 30, 2024
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Neurocrine Biosciences Announces FDA Approval...
Benzinga Newsdesk
Wednesday, April 24, 2024
Wells Fargo Upgrades Neurocrine Biosciences t...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on Neurocrin...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Neurocr...
Benzinga Newsdesk
Tuesday, April 23, 2024
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Vandana Singh
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Neurocrine Biosciences Says Phase 2 SAVITRI S...
Benzinga Newsdesk
Wednesday, April 17, 2024
Wedbush Reiterates Outperform on Neurocrine B...
Benzinga Newsdesk
Tuesday, April 16, 2024
Sentia Medical Sciences Further Extends Resea...
Benzinga Newsdesk
Selection Of The Development Candidate Trigge...
Benzinga Newsdesk
Voyager Therapeutics And Neurocrine Bioscienc...
Benzinga Newsdesk
Voyager Therapeutics And Neurocrine Bioscienc...
Benzinga Newsdesk
Nxera Pharma's NBI-1117568, Backed by Neurocr...
Benzinga Newsdesk
Wednesday, April 10, 2024
Where Neurocrine Biosciences Stands With Analysts
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ne...
Benzinga Newsdesk
Wednesday, April 03, 2024
Neurocrine Biosciences Announces First-Patien...
Benzinga Newsdesk
Thursday, March 28, 2024
Neurocrine Biosciences Announces Initiation O...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch